Pink SheetOncology sponsors will face increased US Food and Drug Administration scrutiny about patient enrollment and site selection for multiregional trials, as well as the relevance of comparator arms to US s
Pink SheetThe European Medicines Agency could this week decide whether Eli Lilly’s Alzheimer’s disease drug, Kisunla (donanemab), should be granted EU marketing authorization, after re-examining its decision to
ScripOn the latest edition of the Scrip M&A Podcast , senior writer Joseph Haas talked about how political uncertainty and continued tight capital markets are affecting biopharmaceutical M&A a
ScripAstraZeneca is the latest large pharma company to announce a major manufacturing investment in the US as the Trump administration threatens to slap tariffs on imports. The drugmaker said July 21 that